YNIOS PHARMA is leading a Critical Care Program to acquire new knowledge for the subsequent development of a drug for the treatment of the Septic Shock.

The research involves an ionic compound to positively impact Septic Shock survival, and identify the appropriate biomarkers to modulate the infusion dosage for optimizing the treatment in function of the disease progression.

The study model is “Fecal Peritonitis Septic Shock” in sheep. This research will open the way for the development of a pharmaceutical form of YNIOS PHARMA  ionic compound in an intravenous (IV) form adapted to Septic Shock treatments.

Septic Shock is a serious condition in which there is inflammation throughout the whole body. This disease can be severe or even life-threatening and leads to multiple organ failure.

The Septic Shock inflammatory process is found in multiple indications, such as Acute Ischemic Stroke and Acute Myocardial Infarction.

YNIOS PHARMA’s goal is to optimize the immune system response to insult for restoring cells and tissues homeostasis and limit damages post Septic Shoc, Acute Ischemic Stroke and Acute Myocardial Infarction.


Transplant rejection is a process in which a transplant recipient’s immune system attacks the transplanted organ or tissue.

Acute rejection may occur any time from the first week after the transplant to 3 months afterward. All recipients have some amount of acute rejection. Chronic rejection can take place over many years. The body’s constant immune response against the new organ slowly damages the transplanted tissues or organ.

Suppressing the immune response may prevent transplant rejection. Immunosuppressants are to be taken lifelong to avoid organ rejection, however, they make patients more likely to develop an infection.

The perfect integrity of the organ to transplant is key to reduce rejection risk. Management of organ integrity starts from the extraction, to transfer, to transplantation, to functioning in the new body. Well achieved, it should minimize the immune system activation of the organ host and reduce rejection.

YNIOS PHARMA’s goal is to improve organ integrity and acceptance to the whole transplantation process.